BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19770132)

  • 1. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
    Yamashita Y; Taketomi A; Itoh S; Harimoto N; Tsujita E; Sugimachi K; Gion T; Maehara Y
    Jpn J Clin Oncol; 2010 Jan; 40(1):24-8. PubMed ID: 19770132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: a pilot study.
    Yamashita Y; Taketomi A; Fukuzawa K; Yoshizumi T; Uchiyama H; Simada M; Shirabe K; Wakasugi K; Maehara Y
    Anticancer Res; 2006; 26(1B):771-5. PubMed ID: 16739352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
    Sohn BS; Yuh YJ; Kim KH; Jeon TJ; Kim NS; Kim SR
    Tumori; 2013; 99(2):139-44. PubMed ID: 23748804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM
    Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma.
    Morine Y; Shimada M; Ikegami T; Imura S; Kanemura H; Arakawa Y; Hanaoka J; Kanamoto M; Nii A
    Hepatogastroenterology; 2009; 56(90):307-12. PubMed ID: 19579588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
    Cereda S; Passoni P; Reni M; Viganò MG; Aldrighetti L; Nicoletti R; Villa E
    Cancer; 2010 May; 116(9):2208-14. PubMed ID: 20187098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
    Knox JJ; Hedley D; Oza A; Siu LL; Pond GR; Moore MJ
    Ann Oncol; 2004 May; 15(5):770-4. PubMed ID: 15111345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
    Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
    Morine Y; Shimada M; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Yamada S; Imura S
    Anticancer Res; 2017 Nov; 37(11):6421-6428. PubMed ID: 29061828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
    Lee J; Kim TY; Lee MA; Ahn MJ; Kim HK; Lim HY; Lee NS; Park BJ; Kim JS;
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):47-52. PubMed ID: 17364190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
    El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
    J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
    Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
    Giuliani F; Gebbia V; Maiello E; Borsellino N; Bajardi E; Colucci G;
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii73-7. PubMed ID: 16760299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: a pilot study.
    Marumoto M; Yamasaki T; Marumoto Y; Saeki I; Harima Y; Urata Y; Hidaka I; Ishikawa T; Takami T; Segawa M; Yamaguchi Y; Uchida K; Terai S; Sakaida I
    Hepatogastroenterology; 2014; 61(129):162-7. PubMed ID: 24895814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
    Meyerhardt JA; Zhu AX; Stuart K; Ryan DP; Blaszkowsky L; Lehman N; Earle CC; Kulke MH; Bhargava P; Fuchs CS
    Dig Dis Sci; 2008 Feb; 53(2):564-70. PubMed ID: 17597402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.